Savara (NASDAQ:SVRA) Trading Down 3.4% – Here’s Why

Savara Inc (NASDAQ:SVRA) shares traded down 3.4% on Wednesday . The stock traded as low as $3.63 and last traded at $3.65. 275,688 shares changed hands during trading, a decline of 77% from the average session volume of 1,204,978 shares. The stock had previously closed at $3.78.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Savara in a research report on Tuesday. Oppenheimer increased their price objective on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, June 26th. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. Finally, Guggenheim upped their price target on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Savara currently has a consensus rating of “Buy” and an average target price of $11.17.

Savara Trading Down 3.4 %

The stock has a market cap of $504.39 million, a PE ratio of -9.86 and a beta of 0.96. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a 50-day simple moving average of $4.26 and a 200-day simple moving average of $4.42.

Savara (NASDAQ:SVRA) last issued its earnings results on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Equities analysts forecast that Savara Inc will post -0.44 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SVRA. Janus Henderson Group PLC raised its position in shares of Savara by 41.1% in the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock worth $12,754,000 after buying an additional 746,407 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Savara during the 4th quarter valued at about $9,683,000. Vanguard Group Inc. grew its holdings in shares of Savara by 2.5% during the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after purchasing an additional 148,673 shares in the last quarter. Swiss National Bank bought a new position in shares of Savara in the first quarter worth approximately $732,000. Finally, Frazier Life Sciences Management L.P. raised its stake in Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.